Karyopharm Therapeutics (KPTI) Total Non-Current Liabilities (2014 - 2025)

Karyopharm Therapeutics has reported Total Non-Current Liabilities for 8 years, with the latest figure at $329.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 5.46% year-over-year to $329.0 million; the trailing twelve-month figure through Dec 2025 stood at $329.0 million (down 5.46% YoY), and the FY2025 full-year result was $329.0 million, down 5.46% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $329.0 million, down from $351.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $374.8 million in Q4 2022, with the low at $236.4 million in Q2 2023.
• Historically, Total Non-Current Liabilities has averaged $285.4 million across 5 years, with a median of $256.0 million in 2021.
• The largest YoY upside for Total Non-Current Liabilities was 51.52% in 2023 against a maximum downside of 34.86% in 2023.
• Karyopharm Therapeutics' Total Non-Current Liabilities stood at $252.0 million in 2021, then jumped by 48.75% to $374.8 million in 2022, then sank by 34.86% to $244.2 million in 2023, then jumped by 42.53% to $348.0 million in 2024, then declined by 5.46% to $329.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $329.0 million (Q4 2025), $351.4 million (Q3 2025), and $270.3 million (Q2 2025), per Business Quant data.